Ionis Pharmaceuticals, Inc. (IONS)
Ionis: Near-Term Launches With Blockbuster Potential Boosts Upside Despite Stock Rally
Ionis Pharmaceuticals maintains a Buy rating as its transformation to a commercial company accelerates, driven by wholly-owned product launches and revenue growth. Q3 results highlight a revenue shift toward Ionis-owned drugs, with Tryngolza outperforming and Dawnzera launching as a differentiated HAE prophylactic. Olezarsen's strong Phase 3 data in sHTG positions IONS for a blockbuster opportunity, despite market competition and ongoing patent litigation with Arrowhead.
Ionis: What Upside Is Left After Shares Rocketed Higher Following Positive Trial Data?
Ionis Pharmaceuticals, Inc. has surged on strong phase-3 trial data and a robust pipeline, but much optimism is already priced in. IONS boasts recent drug launches (Wainua, Tryngolza, Dawnzera) with significant revenue potential, offsetting declining Spinraza royalties amid rising competition. Financials show strong cash reserves but ongoing cash burn; valuation is stretched with a high price/sales ratio and dilution risk.
Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook
IONS' Q3 results top estimates as robust Tryngolza and Wainua sales drive revenue growth. The company raises its 2025 outlook for the third time this year.
Ionis Pharmaceuticals, Inc. (IONS) Q3 2025 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. ( IONS ) Q3 2025 Earnings Call October 29, 2025 11:30 AM EDT Company Participants D. Walke - Senior Vice President of Investor Relations Brett Monia - Founder, CEO & Director Richard S.
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for Ionis Pharmaceuticals (IONS) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Beats Revenue Estimates
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to a loss of $0.95 per share a year ago.
IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal
Ionis' zilganersen hits its phase III goal in Alexander disease, paving the way for a potential FDA filing in early 2026.
Ionis: Recent Approvals, Upcoming Catalysts To Spur Strong Upside (Rating Upgrade)
After years of futility, Ionis' recent regulatory and clinical successes have spurred optimistic market attention. I review Q2/2025 earnings documents together with 09/04/2025 CEO Monia interview and CORE and CORE2 Topline Results transcript for current investment prospects. IONS stock has a boatload of recent and near term upcoming market moving catalysts.
Ionis Pharmaceuticals, Inc. (IONS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 12:20 PM EDT Company Participants Brett Monia - Founder, CEO & Director Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference.
Ionis Pharmaceuticals, Inc. (IONS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 10:15 AM EDT Company Participants Brett Monia - Founder, CEO & Director Conference Call Participants Yanan Zhu - Wells Fargo Securities, LLC, Research Division Presentation Yanan Zhu Senior Equity Analyst Okay. Thank you, everyone, for being here.
IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride
Ionis surges to a 52-week high after Tryngolza shows strong triglyceride reductions and cuts acute pancreatitis risk by 85% in late-stage studies.
Ionis: Dawnzera Approval Kicks Off New Era For Strikingly Undervalued Pharma
Ionis Pharmaceuticals remains a Buy after Dawnzera's FDA approval, which strengthens its pipeline and revenue outlook despite a history of operating losses. Dawnzera's market opportunity in hereditary angioedema is significant, with potential for near-blockbuster status if it captures a 20% share of a ~$5bn market. Upcoming catalysts — including olezarsen's sHTG data and eplontersen's ATTR-CM results — could drive Ionis toward profitability and a higher valuation.
